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Abstract Critical limb ischaemia (CLI) is a particularly severe manifestation of lower limb
atherosclerosis posing a major threat to both limb and life of affected patients. Besides
arterial revascularisation, risk-factor modiﬁcation and administration of antiplatelet
therapy is a major goal in the treatment of CLI patients.
Key elements of cardiovascular risk management are smoking cessation and treatment of
hyperlipidaemia with dietary modiﬁcation or statins. Moreover, arterial hypertension and
diabetes mellitus should be adequately treated.
In CLI patients not suitable for arterial revascularisation or subsequent to unsuccessful
revascularisation, parenteral prostanoids may be considered. CLI patients undergoing
surgical revascularisation should be treated with beta blockers. At present, neither gene nor
stem-cell therapy can be recommended outside clinical trials. Of note, walking exercise
is contraindicated in CLI patients due to the risk of worsening pre-existing or causing new
ischaemic wounds.
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CLI patients are oftentimes medically frail and exhibit signiﬁcant comorbidities.
Co-existing coronary heart and carotid as well as renal artery disease should be managed
according to current guidelines.
Considering the above-mentioned treatment goals, interdisciplinary treatment ap-
proaches for CLI patients are warranted.
Aim of the present manuscript is to discuss currently existing evidence for both the
management of cardiovascular risk factors and treatment of co-existing disease and to
deduct speciﬁc treatment recommendations.
© 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Critical issue
Most of the outlined recommendations apply to peripheral
arterial disease (PAD) patients in general. Thus, it has
to be kept in mind that recommendations are frequently
extrapolated to the subgroup of PAD with critical limb
ischaemia (CLI).
1. Smoking
Smoking is the most important risk factor in PAD patients.
The extent of smoking exposure correlates with PAD disease
severity, rates of lower limb amputation, bypass re-occlusion
as well as with mortality.1––3 Thus, CLI patients should be
advised to quit smoking with the aim to reduce the risk of
adverse cardiovascular events and amputation.
Physician smoking cessation advice coupled with a formal
smoking cessation programme and nicotine replacement
was shown to be associated with a 22% cigarette smoking
cessation rate out to 5 years.1 In this randomised controlled
trial (RCT), cessation rate was only 5% in the group of
patients not undergoing this programme. Fourteen years
post randomisation, the group of patients on this programme
still exhibited a signiﬁcant survival beneﬁt as compared to
the control group.
The clinical utility of nicotine replacement therapy was
assessed in a Cochrane review4 for which a total of 132 RCTs
were summarised. All of the commercially available forms
of nicotine replacement therapy (gum, transdermal patch,
nasal spray, inhaler and sublingual tablets/lozenges) were
shown to increase the odds of successfully stopping cigarette
smoking by 50––70%.
A number of RCTs supported the use of bupropion, an
antidepressive agent, in cigarette smokers with cardiovascu-
lar disease. Abstinence rates were reported to be 34%, 27%
and 22% at 3-, 6- and 12-month follow-up as compared with
15%, 11% and 9%, respectively, with placebo treatment.5
Finally, the efﬁcacy of nicotine receptor partial agonists
was assessed in a recently published systematic Cochrane
review summarising 11 RCTs with more than 10,300
patients.6 In this analysis, the pooled risk ratio for
continuous smoking abstinence at 6 months or longer
for varenicline vs. placebo was 2.31 (95%CI 2.01––2.66).
Moreover, varenicline was shown to be superior to bupropion
[pooled RR for varenicline vs. bupropion at 1 year: 1.52
(95%CI 1.22––1.88)].
Of note, smoking cessation may be associated with
important beneﬁts such as improvement of respiratory
symptoms7 and vascular tone already during short-term
follow-up.8
Recommendations
CLI patients should be strongly and repeatedly advised to
stop smoking. (Level 2a; Grade B)
Smoking cessation rates can be improved by offering
medical advice, group counseling session, nicotine re-
placement, nicotine receptor partial agonists (varenicline)
or antidepressant drug therapy (bupropion). (Level 1a;
Grade A)
2. Hyperlipidaemia
Increased cholesterol, low-density lipoprotein (LDL), triglyc-
eride and lipoprotein (a) concentrations are independent
major PAD risk factors. Moreover, PAD is considered a
coronary heart disease risk equivalent.9
The Heart Protection Study assessed the impact of
statin intake on mortality and fatal and non-fatal vascular
events.10 For that purpose, a total of 20,536 patients
with coronary artery disease (CAD), other arterial occlusive
disease or diabetes mellitus were randomly assigned
to 40mg simvastatin daily vs. placebo. In that study,
all-cause mortality and cardiac death were signiﬁcantly
reduced by statins irrespective of the patients’ cholesterol
concentration. Importantly, simvastatin reduced major
vascular events by 22% in the subgroup of PAD patients.
Remarkably, there was no threshold cholesterol value below
which statin therapy was not associated with clinical
beneﬁts.
In the 4S study (Scandinavian Simvastatin Survival Study),
a total of 4444 coronary heart disease patients were
randomised to simvastatin vs. placebo.11 In the statin group,
the risks for mortality, stroke and intermittent claudication
were signiﬁcantly reduced. The authors concluded that
long-term treatment with simvastatin is safe and improves
survival in coronary heart disease patients.
In the PREVENT III study a total of 1404 CLI patients un-
dergoing lower extremity bypass grafting were randomised
to edifoligide vs. placebo aimed at preventing neointimal
hyperplasia and vein graft failure.12 In that trial, statin
use was associated with a signiﬁcant reduction of 1-year
mortality in a propensity-score adjusted model.
In a Cochrane review including 18 RCTs with 10,049
participants the clinical utility of statins in PAD patients
was scrutinised.13 Lipid-lowering medication was shown to
be associated with a beneﬁcial effect on the incidence
of total cardiovascular events, primarily due to an overall
reduction in coronary events (OR: 0.8; 95%CI 0.7––0.9).
Statins were identiﬁed as the only type of drug for which
consistent, clear evidence of a beneﬁcial effect on total
cardiovascular events, total coronary events and stroke was
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available. The greatest evidence was with simvastatin in
people with a blood cholesterol level of at least 3.5mmol/L
(i.e. 63mg/dL).
At present, there is no study indicating that diet
alone impacts on cardiovascular events in patients with
atherosclerosis. It is recommended, however, that therapy
for increased cholesterol concentrations begins with lifestyle
modiﬁcations aimed at lowering elevated cholesterol.14
Thus, dietary modiﬁcation and pharmacologic intervention
for dyslipidaemia should be tailored to meet the current
guidelines for high-risk patients.
In addition to the above-described beneﬁts, statins may
prevent plaque instability and thrombosis due to their
pleiotropic effects such as improvement of endothelial
function, reduction of inﬂammation, and stabilisation of
atherosclerotic plaques.15
Current recommendations for the management of lipid
disorders in PAD are to achieve an LDL cholesterol level of
<100mg/dL and to treat the pattern of increased triglyceride
and low high-density lipoprotein (HDL).16,17
Recommendations
In CLI patients, statins should be the primary agents
to lower LDL cholesterol levels to reduce the risk of
cardiovascular events. (Level 1a; Grade B)
For CLI patients, LDL cholesterol should be <100mg/dL.
(Level 5; Grade D)
Dietary modiﬁcation is aimed at controlling body weight
and lipid disorders. (Level 5; Grade D)
Statins are indicated for secondary prevention of
cardiovascular events in patients with CLI. (Level 1a;
Grade B)
3. Arterial hypertension
Arterial hypertension is a major independent risk factor for
PAD. Current hypertension guidelines advocate aggressive
treatment of elevated bood pressure in patients with
atherosclerosis. Current treatment goals of antihypertensive
therapy are arterial blood pressures of <140/90mmHg.
Moreover, blood pressure should be <130/80mmHg if the
patient also has diabetes or renal insufﬁciency.18,19 To
achieve these results, all drugs capable of lowering arterial
blood pressures can be considered for the prevention of
vascular events. Many patients may require agents of various
classes to achieve the above-mentioned blood pressure
goals. Evidence for speciﬁc blood-pressure lowering drugs
in PAD patients is only available for angiotensin-converting-
enzyme (ACE) inhibitors and beta blockers. It has to be kept
in mind, however, that an acute reduction of blood pressure
may result in a further impairment of lower limb perfusion
in CLI patients not undergoing revascularisation.
The speciﬁc beneﬁt of ramipril, an ACE inhibitor, in PAD
patients was documented by results from the HOPE (Heart
Outcomes Prevention Evaluation) study in 4046 patients.20 In
the subgroup of PAD patients, there was a 22% risk reduction
in the composite endpoints of myocardial infarction, stroke
or cardiovascular death in patients randomised to ramipril
as compared to placebo. Interestingly, this clinical beneﬁt
was independent of lowering of blood pressure. Thus,
ACE inhibitors may exert beneﬁcial effects such as plaque
stabilisation and prevention of atherosclerosis progression
beyond those of lowering arterial blood pressure. However,
it has to be kept in mind that this study was not carried
out exclusively in CLI patients. Thus, as for other risk factor
interventions, data are largely extrapolated from a general
PAD but not speciﬁcally CLI population.
Based on results from initial studies with non-selective
beta blockers such as propanolol, beta-adrenergic blocking
drugs have previously been discouraged in PAD due to their
potential to reduce cardiac output and to prevent beta-
2-receptor-mediated skeletal muscle vasodilation.21 Two
meta-analyses of studies published in patients with mild and
moderate lower limb ischaemia did not conﬁrm the intake
of beta blockers to be associated with exacerbation of PAD
symptoms.22,23 Thus, the above-mentioned concern might
have been overstated, especially in patients treated with
a beta-1 selective drug, especially since PAD patients with
coronary disease may have additional cardiac protection
with beta blockers. Therefore, beta-adrenergic-blocking
agents may be considered for the treatment of arterial
hypertension in PAD patients.
The clinical utility of peri-operative administration of
beta blockers is controversial. Use of beta blockers was
shown to be associated with signiﬁcant reductions of peri-
operative myocardial ischaemia and infarction in various
surgical settings.24 In the POISE (peri-operative ischaemic
evaluation) study, a total of 8351 patients with, or
at risk of, atherosclerotic disease who were undergoing
non-cardiac surgery were randomised to extended-release
metoprolol succinate (n = 4174) vs. placebo (n = 4177).25
Study treatment had been started 2––4 hours before surgery
and continued for 30 days. The primary endpoint, a
composite of cardiovascular death, non-fatal myocardial
infarction, and non-fatal cardiac arrest, was more frequently
observed in the beta-blocker cohort (5.8%) as compared
to the placebo group (6.9%) (HR: 0.84, 95%CI 0.70––
0.99; p = 0.0399). Fewer patients in the metoprolol group
experienced myocardial infarction (4.2% vs. 5.7%, HR: 0.73,
95%CI 0.60––0.89; p = 0.0017). However, both mortality
(3.1% vs. 2.3%, HR: 1.33, 95%CI 1.03––1.74; p = 0.0317) and
stroke (1.0% vs. 0.5%, HR: 2.17, 95%CI 1.26––3.74; p = 0.0053)
rates were higher in the metoprolol compared to the placebo
group. Of note, the dose of beta blockers administered in the
POISE trial was higher as compared to that used in earlier
studies.26
Recommendations
CLI patients with arterial hypertension should be treated
with antihypertensive medical therapy aimed at lowering
cardiovascular mortality. (Level 1a; Grade B)
Treatment goals for CLI patients with arterial hyperten-
sion: arterial blood pressure should be <140/90mmHg and
<130/80mmHg in case of concomitant diabetes mellitus
or renal insufﬁciency. (Level 1a; Grade B)
ACE inhibitors are recommended in CLI patients.
(Level 2a; Grade B)
Beta-adrenergic blocking drugs are not contraindicated in
CLI patients. (Level 1a; Grade B)
Beta-adrenergic blocking drugs may be administered to
patients undergoing surgical lower limb revascularisation.
(Level 1a; Grade D)
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4. Diabetes mellitus
Diabetes mellitus is independently associated with PAD
and its progression to CLI. Limb salvage rates in diabetic
CLI patients have been reported to be lower as compared to
those of non-diabetic patients, and diabetes was shown to be
an independent risk factor for amputation and complications
in CLI patients.
In the STENO-2 study, 160 diabetics were randomly
assigned to either intensiﬁed or conventional therapy
(control of blood glucose, statins, antithrombotic therapy,
blood pressure control). After 13.3 years, intensive therapy
was associated with a signiﬁcant reduction of risks of all-
cause death (HR: 0.54, 95%CI 0.32––0.89; p = 0.02, risk
reduction: 20%) and cardiovascular death (HR: 0.43, 95%CI
0.19––0.94; p = 0.04, risk reduction: 13%).27
In the UKPDS study (United Kingdom Prospective Diabetes
study), a total of 5000 patients with newly diagnosed
diabetes mellitus were randomised to conventional therapy
(dietary restrictions as primary treatment approach) vs.
intensiﬁed therapy (either sulfonylurea or insulin or
metformin).28 Although between-group differences in HbA1c
levels perished after the ﬁrst year, intensiﬁed therapy was
associated with risk reductions for microvascular disease,
myocardial infarction and death from any cause as well as
for any diabetes-related endpoint.
In contrast to these ﬁndings, it has recently been called
into doubt if intensive glucose lowering is truly beneﬁcial:
In the ADVANCE (Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation) trial,
a total of 11,140 patients with type 2 diabetes were
randomised to undergo either standard glucose control or
intensive glucose control to achieve a glycated haemoglobin
value of 6.5% or less.29 In that study, rates of microvascular
complications, but not macrovascular complications or
cardiovascular deaths were improved by intensive diabetes
therapy during a follow-up of 5 years.
Moreover, the ACCORD (Action to Control Cardiovascular
Risk in Diabetes) study randomised participants with
type 2 diabetes and cardiovascular disease or additional
cardiovascular risk factors to receive intensive therapy
(targeting a HbA1c <6.0%) or standard therapy (targeting a
level of 7––7.9%).30 The study was prematurely stopped after
3.4 years due to an increased mortality in the intensively
treated group, although the rates of non-fatal myocardial
infarction and stroke were lower in the intensively treated
group by that time. At 5 years, the use of intensive therapy
for 3.7 years reduced 5-year non-fatal myocardial infarctions
but increased 5-year mortality.
Whether the above-mentioned beneﬁts of thorough
diabetes control yield improvements in functional lower limb
outcomes such as limb salvage or freedom from repeated
revascularisation in CLI patients has yet to be determined.
Recommendation
Blood glucose levels should be monitored in CLI patients
with a haemoglobin A1c (HbA1c) goal of <7.0%. (Level 5;
Grade D)
5. Antiplatelet therapy
While the clinical utility of antiplatelet therapy for
secondary prevention of patients with atherothrombosis is
without controversy, there are currently no convincing data
showing a delay or reduction of the progression of lower
limb atherothrombotic lesions by antiplatelet therapy. In
contrast, studies assessing antiplatelet therapy for primary
prevention or peripheral vascular events are scarce and
results have been conﬂicting so far.31
The CAPRIE (Clopidogrel versus Aspirin in Patients at
Risk of Ischaemic Events) trial demonstrated that the
combined risk of death from vascular causes, myocardial
infarction, and stroke was signiﬁcantly, albeit moderately
(number-needed-to-treat with clopidogrel in comparison
with aspirin: 87 patients) lower with clopidogrel (75mg/day)
compared with aspirin (325mg/day).32 Of note, the beneﬁts
of clopidogrel were most pronounced in the subgroup of
PAD patients in that trial.
The Antithrombotic Trialists’ Collaboration meta-analysis
found a 23% reduction in serious vascular events in 9214
PAD patients within 42 trials.33 In the primary meta-
analysis, however, no signiﬁcant reduction of cardiovascular
events could be demonstrated for PAD patients without
further atherothrombotic lesions in other arterial terri-
tories. In a subsequent summary including study data
on various antiplatelet drugs such as acetylsalicylic acid,
clopidogrel, ticlopidine, dipyridamole and picotamide,
a 23% risk reduction of ischaemic results could be
shown for all PAD patients.34 Moreover, since clinically
inapparent concomitant coronary heart disease is present
in many PAD patients,35 it might be logical to extend the
administration of antiplatelet therapy to asymptomatic PAD
patients, although various questions related to this issue are
still pending.
The precise daily dose for aspirin remains to be
determined. Low-dose aspirin (75––325mg) is as effective as
higher doses.36 However, higher doses of aspirin result in
increased bleeding rates37 and very low doses (<75mg) are
less effective.36
The daily dose of clopidogrel for secondary prevention of
PAD patients is 75mg. Ticlopidin was assessed within various
PAD studies and reduces the risk for myocardial infraction,
stroke and vascular death.38 However, its clinical utility is
limited by potential side effects such as neutropenia and
thrombopenia.
In the absence of other indications for oral anticoagula-
tion, the latter is not indicated in PAD patients. Even more
so, it was shown to be associated with higher bleeding rates
if added to aspirin, without lowering rates of cardiovascular
events.39
Two RCTs analysed whether or not antiplatelet therapy
may improve patency rates subsequent to lower limb
endovascular therapy. In the ﬁrst study,40 a total of
199 patients undergoing femoropopliteal angioplasty were
randomised to dipyridamole (225mg) combined with 900mg
of aspirin vs. dipyridamole (225mg) with 300mg of aspirin
vs. placebo. Patients from both dipyridamole arms showed
higher patency rates as compared to those on placebo.
In the second study,41 a total of 223 patients after
iliac or femoropopliteal angioplasty were randomised to
placebo vs. 50mg of aspirin plus 400mg of dipyridamole.
Primary patency was comparable in both groups. However,
a substantial limitation of that study was that a signiﬁcantly
higher number of iliac angioplasties had been included in the
placebo arm, which was shown to be associated with lower
restenosis rates.
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Moreover, the CASPAR study randomised a total of 425
patients undergoing below-the-knee bypass grafting to
either aspirin 75––100mg per day alone or aspirin 75––100mg
per day plus clopidogrel 75mg per day.42 In that trial a
combination of clopidogrel plus aspirin did not improve
lower limb or systemic outcomes. However, dual antiplatelet
therapy was associated with a lower rate of a composite
of index-graft occlusion or revascularisation, above-ankle
amputation of the affected limb, or death as compared to
aspirin alone without increasing bleeding risks.
Four studies analysed whether a high dose (90––1000mg)
of aspirin is more potent in inhibiting reocclusions
subsequent to endovascular therapy.43––45 Six months post-
interventionally, there was no beneﬁt of high-dose aspirin,
whereas the rates of gastrointestinal side effects increased
with higher doses.
In line with current standards in coronary endovascular
revascularisation,46 a combination of aspirin with clopidogrel
is used subsequent to peripheral arterial stent implantation.
However, at present there are no dedicated study data
for the peripheral arteries. The CAMPER (Clopidogrel and
Aspirin in the Management of Peripheral Endovascular Revas-
cularisation) study had been started in the USA to evaluate
the combined administration of aspirin and clopidogrel in
patients undergoing endovascular revascularisation of the
femoropopliteal arteries. Due to insufﬁcient numbers of
patients randomised, this study was stopped prematurely.
Recommendations
Antiplatelet (aspirin or clopidogrel) therapy is indicated
in patients with symptomatic peripheral arterial disease.
(Level 1a; Grade A)
Both aspirin and clopidogrel reduce rates of cardiovascular
events in patients with symptomatic peripheral arterial
disease. (Level 1b; Grade A)
In line with recommendations for patients with coronary
heart disease, an intermittent administration of dual
antiplatelet therapy (aspirin plus clopidogrel) may be
considered for patients undergoing stent implantation or
drug-eluting balloon angioplasty of femoropopliteal or
infrapopliteal arteries. (Level 5; Grade D)
A combination of clopidogrel and aspirin may be consid-
ered as antithrombotic regimen in patients undergoing
below-the-knee prosthetic bypass grafting. (Level 1b;
Grade A)
6. Vasoactive drugs
In patients with CLI not eligible for arterial reconstruction,
prostanoids are the only vasoactive drugs with proven
efﬁcacy. The currently available data support the use
of prostanoids in patients unsuitable for lower limb
revascularisation or in patients in whom revascularisation
attempts have failed.
Two randomised double-blind studies with prostaglandin E-1
have shown a clinical beneﬁt with regard to the reduction
of ulcer size.47,48 A further RCT with iloprost showed higher
limb salvage and survival rates in the prostanoid group.49
Creutzig recently concluded, in a meta-analysis of
randomised placebo-controlled trials50 including data from
7 studies totalling 643 patients, that for patients with PAD
stage III or IV PGE1 therapy not only has signiﬁcant beneﬁcial
effects over placebo on ulcer healing and pain relief, but
also increases the rate of patients surviving with both legs
after 6 months follow-up.
A further meta-analysis has shown that a 2- to 4-week
treatment with iloprost reduces rest pain and ulcer size.51
Moreover, iloprost was associated with a higher rate of
amputation-free survival at 6 months. It has to be kept in
mind, however, that the use of iloprost is not approved in
all European countries.
Further vasoactive drugs such as naftidrofuryl, buﬂomedil
or pentoxifylline did not show additional beneﬁt with regard
to reduction of amputations and wound healing.2,52
Recommendation
Parenteral prostanoids can be used in patients with critical
limb ischaemia not suitable for arterial revascularisation
or after unsuccessful revascularisation. (Level 1b;
Grade B)
7. Gene and stem-cell therapy
The clinical utility of gene and stem-cell therapy is not
yet fully understood. While it has been shown that both
treatment approaches are well tolerated, a signiﬁcant
clinical beneﬁt has yet to be shown for either method.
Gene therapy has been clinically evaluated since 1994
within at least 6 placebo-controlled randomised clinical
phase II studies and within one placebo-controlled phase III
study. The four studies assessing gene therapy in CLI patients
were positive for various endpoints.53––56 However, only
amputation and mortality should be considered clinically
relevant endpoints in this regard. Only the application
of riferminogen pecaplasmid [non-viral gene construct for
the ﬁbroblast growth factor 1 (NV1FGF)] was shown to be
associated with a reduction of the rate for major amputa-
tions and improved amputation-free survival as compared to
placebo within the TALISMAN 201 study.54 Further positive
endpoints of other studies included angiographically veriﬁed
improvements of arterial vascularisation during follow-up,
improvements in transcutaneously measured oxygen partial
pressure and further haemodynamic parameters.
Based on positive results from the above-mentioned
TALISMAN 201 study,54 the currently largest gene therapy
trial was initiated including 525 CLI patients without any
option for endovascular or surgical revascularisation from
30 countries and 171 hospitals. With 2-week intervals eight
injections of a gene construct vs. placebo were applied into
thigh and calf of the affected limb. After 12 months, there
was no signiﬁcant difference in amputation-free survival and
time to major amputation comparing the NV1FGF with the
placebo group.57
Since progenitor cells have been identiﬁed as a participant
in angiogenesis, their role in therapeutic clinical applications
has been assessed. The ﬁrst clinical trial investigating the
use of progenitor cells in CLI patients was published in
2002.58 Use of bone-marrow-derived mononuclear cells was
associated with improvements in ABI, TcPO2 and pain-free
walking time out to 6 months. Subsequent to this trial
with a small sample size, this concept was investigated in
various non-randomised studies with small sample sizes.59
To date, there are no double-blind RCTs assessing the use
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of bone-marrow-derived or mobilised mononuclear cells in
PAD patients. The scientiﬁc community is currently waiting
for results of at least 10 randomised controlled cell therapy
trials.59,60 Until data from these studies are availabe, the
application of stem cells cannot be recommended outside
clinical studies.
Recommendation
Neither gene nor stem cell therapy can be recommended
as a treatment for CLI outside clinical trials. (Level 5;
Grade D)
8. Exercise and lower limb rehabilitation
In contrast to patients with intermittent claudication, no
data assessing the efﬁcacy of walking exercise in CLI are
available. Considering the risk of causing or worsening
already present ischaemic wounds, walking exercise is
contraindicated in patients with CLI not undergoing
revascularisation.
Recommendation
Due to the risk of worsening pre-existing or causing new
ischaemic wounds in the affected lower limb, walking
exercise may be contraindicated in CLI patients not
undergoing revascularisation. (Level 5; Grade D)
9. Treatment of co-existing disease
This section covers the management of typical co-existing
diseases in patients presenting with CLI and with important
impact on morbidity and mortality.
9.1. Coronary artery disease (CAD)
Patients with PAD have a high prevalence of CAD,
which strongly increases the risk for cardiac mortality
and morbidity.61,62 Therefore, all PAD patients should be
considered at high risk for clinically signiﬁcant ischaemic
heart disease, for which guidelines exist.63,64 Cardiac risk
is related to urgency, extent, type and duration of
the intervention planned. Patients should be evaluated
for evidence of CAD. Treatment decisions for coexisting
CAD should be based on current practice guidelines and
the intended treatment modality. Patients with unstable
symptoms (acute coronary syndrome, congestive heart
failure) should be referred to a cardiovascular physician
for appropriate diagnosis and treatment. Most patients with
severe cardiac symptoms will require coronary angiography
to determine the appropriate means for revascularisation.
For patients with stable CAD, management should be
guided by the severity of the symptoms and comorbid
conditions. All patients should be given appropriate medical
therapy to treat symptoms and atherosclerotic risk factors.
Cardiac assessment scores may be useful in the context of
patients being considered for peripheral revascularisation.65
In patients with a high cardiac risk assessment score, current
guidelines recommend further evaluation of the patient
for possible coronary revascularisation.24 However, in the
recent Coronary Artery Revascularization Prophylaxis (CARP)
trial of patients with peripheral vascular disease who were
considered high risk for peri-operative complications and
had signiﬁcant CAD, coronary revascularisation did not
reduce peri-operative myocardial infarction or overall
mortality.66
Delay to vascular surgery was signiﬁcantly longer in
patients who underwent coronary revascularisation com-
pared to patients who did not, which in CLI patients
is often counterproductive. Therefore, the strategy of
a pre-emptive coronary revascularisation prior to urgent
peripheral vascular surgery should not normally be pursued.
In most patients, peri-operative use of beta-adrenergic-
blocking agents is associated with reduced cardiovascular
risks of surgery. Recent studies have shown that beta-
adrenergic blockade with bisoprolol signiﬁcantly decreases
the risk for cardiovascular events during vascular surgery and
afterwards.67,68 Besides controlling symptoms of myocardial
ischaemia, treatment with beta-blocking agents also has
the beneﬁt of favourably inﬂuencing prognosis in these
patients.69 Starting beta-adrenergic-blocking treatment
shortly before surgery (POISE), however, was not proven to
be beneﬁcial in terms of mortality and stroke as outlined
above.25
Recommendations
Routine treatment with beta blockers before vascular
surgery is recommended. (Level 1b; Grade B)
Routine coronary revascularisation before vascular surgery
is not recommended. (Level 1b; Grade B)
9.2. Carotid artery disease
The prevalence of carotid artery disease in patients with
PAD is 10––30%, and there are no speciﬁc data for CLI.
Since PAD patients are at an increased risk of stroke
it might be reasonable to screen those patients for
carotid artery disease routinely. Further evaluation and
consideration for revascularisation should be based on
current guidelines.70 One must keep in mind that CLI patients
with limited life expectancy will hardly beneﬁt from
carotid endarterectomy or stenting for asymptomatic carotid
disease.
9.3. Renal artery disease
PAD patients are at an increased risk for renovascular hyper-
tension. The management of patients with atherosclerotic
renal artery disease and PAD is focused on preservation of
renal function and control of hypertension. Patients with
hypertension should be assessed by renovascular ultrasound
imaging. In the presence of signiﬁcant renal artery stenosis
treatment should be based on current guidelines.2,71––74 These
patients should be referred to an appropriate vascular
physician. Again, one must keep in mind that CLI patients
will hardly beneﬁt from treatment of renal artery stenosis.
10. Health economics of risk-factor
interventions
Unlike in PAD patients,2 no literature is available on
health economics of risk-factor intervention speciﬁcally
in CLI patients. CLI patients differ importantly from
claudicants. CLI patients are suffering from ischaemic lower
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limb pain, depression, social isolation and fear of losing their
limb. They tend to adhere more to their habits and changing
any life style issue can be an important task.
Measuring compliance of chronic patients to risk-factor
interventions is difﬁcult since these patients are treated by
numerous health professionals at the same time. Health and
economic beneﬁts are obviously worse in CLI patients than
in primary preventions since life expectancy in CLI patients
is signiﬁcantly reduced. An additional difﬁculty is that health
and economic beneﬁts are delayed while resources for
treatment have to be expended at once. Moreover, given
that numerous interventions are performed by means of a
variety of drugs, costs differ importantly between health-
economic systems in different countries. Costs in health
economics can be expressed as average costs for 1 year of
life gained.
10.1. Cost-effectiveness of smoking cessation
interventions
No publications are available for CLI patients. Although there
is good evidence for smoking cessation in peripheral artery
disease, cessation programmes might not be successful in
CLI patients. Training and group counseling sessions may
not be followed in normal range. Antidepressant therapy
(bupropion) and nicotine replacement could therefore still
be considered by the treating physician.5
10.2. Cost-effectiveness of pharmacologic interventions
Studies on diabetes, dyslipidaemia and hypertension have
shown for primary intervention that compliance with
guidelines is usually cost effective with a range of $20,000
to $30,000 per year of life gained.75,76 Statin drug costs
represented between 45% and 68% of the overall primary
preventive cost of coronary heart disease.77 The speciﬁc
costs differ depending on the guidelines used. Studies on
cost-effectiveness in CLI patients are currently lacking.
Considering that CLI patients would beneﬁt from the same
medication as claudicants, i.e. treatment by a combination
of aspirin, a statin, a beta blocker and a diuretic,78 the costs
per additional quality-adjusted life year (QALY) would be
£20,000 to £40,000. On top of that in CLI patients pain-relief
medication, antibiotics, ACE inhibitors and more should be
added.
Recently the term “cost per major event averted” has
been created since studies have failed to show a beneﬁt on
mortality. For example, the cost effectiveness of 40mg/day
simvastatin in high-risk patients is £4500 (95%CI £2300––
7400) per major vascular event averted, but the result is
highly dependent on the cost of statin.79
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